Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial.

Am J Respir Crit Care Med · 2020 · PMC7301746 · PMID 32142372

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Levels of tetranor-PGDM also tended to be lower in the omalizumab phase than in the placebo phase throughout the treatment period, although this did not reach statistical significance at Day 7, Month 2, or Month 3.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.